Melanoma molecular classes and prognosis in the postgenomic era

Elisa Tremante, Agnese Ginebri, Elisa Lo Monaco, Pasquale Frascione, Franco Di Filippo, Irene Terrenato, Maria Benevolo, Marcella Mottolese, Edoardo Pescarmona, Paolo Visca, Pier Giorgio Natali, Patrizio Giacomini

Research output: Contribution to journalArticlepeer-review


Gene expression profiling is a powerful method to classify human tumours on the basis of biological aggressiveness, response to therapy, and outcome for the patient, but its application in melanoma lags behind that of other cancers. From more than 100 articles available on the topic, we selected 14 focusing on patients' outcome. We review and briefly discuss salient findings, and list ten reasons why melanoma molecular classes are not yet used in clinical diagnosis and prognosis. The available evidence suggests that we are on the verge of creating a framework for the use of melanoma molecular classes in prognosis, but so far there is little consensus to put together informative diagnostic and prognostic gene sets.

Original languageEnglish
JournalThe Lancet Oncology
Issue number5
Publication statusPublished - May 2012

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Melanoma molecular classes and prognosis in the postgenomic era'. Together they form a unique fingerprint.

Cite this